ArticleClinical rheumatology2010
Successful treatment of severe nodular scleritis with adalimumab.
Article in Clinical rheumatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial.American journal of ophthalmology · 2016Trial
- Adalimumab plus Conventional Therapy versus Conventional Therapy in Refractory Non-Infectious Scleritis.Journal of clinical medicine · 2022Article
- Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review.Ophthalmology and therapy · 2021Review
- Multinodular scleritis in a patient with rheumatoid arthritis.Clinical rheumatology · 2021Article
- Effectiveness of pharmacological agents for the treatment of non-infectious scleritis: a systematic review protocol.Systematic reviews · 2020Article
- Article
- Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS)-report 4: analysis and outcome of scleritis in an East Asian population.Journal of ophthalmic inflammation and infection · 2017Article
- Refractory necrotizing scleritis successfully treated with adalimumab.Journal of ophthalmic inflammation and infection · 2016Article
- [Diagnosis and treatment of episcleritis and scleritis].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2016Review
- Flurbiprofen: A Nonselective Cyclooxygenase (COX) Inhibitor for Treatment of Noninfectious, Non-necrotizing Anterior Scleritis.Ocular immunology and inflammation · 2016Article
- Biologic therapy for refractory scleritis: a new treatment perspective.International ophthalmology · 2015Review
- Pharmacotherapy of scleritis: current paradigms and future directions.Expert opinion on pharmacotherapy · 2013Review
- Systemic treatments for noninfectious vitreous inflammation.Mediators of inflammation · 2013Review
- [Extra-articular manifestations of rheumatoid arthritis].Zeitschrift fur Rheumatologie · 2012Article
- Systemic treatment of vitreous inflammation.Mediators of inflammation · 2012Review
- Adalimumab in the treatment of recurrent idiopathic bilateral nodular scleritis.Oman journal of ophthalmology · 2011Article
- [Diseases of the outer eye in rheumatoid arthritis].Zeitschrift fur Rheumatologie · 2010Review
- Management of noninfectious scleritis.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular features may occur in longstanding rheumatoid arthritis. Among them, scleritis represents the most frequent manifestation of ophthalmologic rheumatoid disease. There are three types of anterior scleritis: diffuse, nodular, and necrotizing with and without inflammation (scleromalacia perforans). Nodular scleritis is the second cause of anterior scleritis representing 20% of all types of scleritis. The conventional treatment of nodular scleritis consists in topical steroids and DMARDS. In severe cases, the therapy with immunosuppressive agents to avoid complications is necessary. We describe a 46-year-old woman presented right nodular scleritis with rheumatoid arthritis. She was treated initially with topical steroids and DMARDs but was unable to received systemic steroids due to left open angle glaucoma in the opposite eye. After an ocular exacerbation, we initiated adalimumab with complete resolution of nodular scleritis. This is the first report of adalimumab in the treatment of nodular scleritis. Adalimumab could be a good alternative in patients with severe nodular scleritis who fail to have conventional treatment with DMARDs and unable to receive systemic steroids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.